Results 171 to 180 of about 70,315 (252)

Prognostic significance of prior alcohol use disorder in patients with presumed metabolic dysfunction‐associated steatotic liver disease: A large multi‐center cohort study

Addiction, EarlyView.
Abstract Background and aims Alcohol use disorder (AUD) follows a chronic, relapsing course but is often overlooked when alcohol consumption is minimal at the time of evaluation. We aimed to assess the prognostic impact of a prior AUD diagnosis on liver‐related outcomes in patients with presumed metabolic dysfunction‐associated steatotic liver disease (
Butros Fakhoury, Jinye Liu, Vinay Jahagirdar, Kaanthi Rama, Gerald Scott Winder, Luis Antonio Díaz, Juan Pablo Arab   +6 more
wiley   +1 more source

A Case Report on Plasma Exchange for Acute-on-Chronic Liver Failure from Severe Alcoholic Hepatitis with Failed Steroid Therapy. [PDF]

Case Rep Gastroenterol
Annamalai NVA, Kang G, De Roza MA.
europepmc   +1 more source

Clinical Need and Research Investment for Liver Cancer in Australia

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Liver cancer incidence and mortality rates have been rising in comparison to other common cancers, but research funding has not been commensurate. ABSTRACT Aim This study aims to better understand factors driving the rising burden and costs of primary liver cancer (PLC) in Australia, identify key epidemiological trends, and ascertain investment in PLC ...
Romario Nguyen, Fatema Safri, Ankur Sharma, Jessica Howell, Stuart K. Roberts, Simone I. Strasser, Amany Zekry, Alan Wigg, Leon A. Adams, Michael Wallace, Golo Ahlenstiel, Eleonora Feletto, Karen Canfell, Tracey O'Brien, Jacob George, Liang Qiao   +15 more
wiley   +1 more source

Profile of serum levels of TNF-α, IL-1β, IL-6, IL-8, IL-12, adiponectin, and vitamin D₃ in male Polish patients with acute alcoholic hepatitis and alcoholic cirrhosis. [PDF]

Clin Exp Hepatol
Tomasiuk R, Wiacek M.
europepmc   +1 more source

Clinical Burden of Symptomatic HEV‐3 Infection in Southern Spain

Alimentary Pharmacology &Therapeutics, EarlyView.
Clinical burden of symptomatic HEV‐3 infection in southern Spain. Between 2022 and 2025, 1124 patients with acute hepatitis, defined as ALT ≥ 3 times the upper limit of normal and negative screening for HAV, HBV, HCV, EBV and CMV, were evaluated in Andalusia.
María Casares‐Jimenez, Claudia Ferreira‐Tata, Isabel Viciana, Carolina Freyre‐Carrillo, Pedro Lopez‐Lopez, Ana Belen Perez, Berta Becerril‐Carral, Ana Fuentes, Juan Macías, Lucia Rios‐Muñoz, Francisco Franco‐Alvarez de Luna, María Teresa Cabezas‐Fernandez, Diana Corona‐Mata, Antonio Rivero‐Juarez, Antonio Rivero   +14 more
wiley   +1 more source

Bacillus cereus Sepsis in a Patient with Severe Alcoholic Hepatitis. [PDF]

Intern Med
Suto K, Hayashi M, Fujita M, Abe K, Takahashi A, Ohira H.   +5 more
europepmc   +1 more source

A Distinct Immune Signature Characterizes Cirrhosis in Ethiopian Individuals With Chronic HBV Infection

Alimentary Pharmacology &Therapeutics, EarlyView.
Cirrhosis patients with untreated HBV in Ethiopia exhibit a distinct immune profile marked by depletion of NK cells, B cells, and T cells, alongside an expanded CD38+HLA‐DR+ CD8 T‐cell population. ABSTRACT Background and Aims The immune cell phenotype of African patients living with chronic hepatitis B virus (HBV) infection is rarely described, despite
Julia MacLeod, Fikadu G. Gudissa, Asiya Jeylan, Nega Berhe, Hailemichael Desalegn, Lasse Rossvoll, Asgeir Johannessen, Niklas K. Björkström, Dag Henrik Reikvam, Annika Niehrs   +9 more
wiley   +1 more source

Long‐Term Safety and Efficacy of Obeticholic Acid in Patients With Primary Biliary Cholangitis: Final Results of the POISE Long‐Term Safety Extension

Alimentary Pharmacology &Therapeutics, EarlyView.
In the POISE open‐label extension, patients with primary biliary cholangitis with inadequate response or intolerance to ursodeoxycholic acid received long‐term obeticholic acid (OCA) treatment. Findings demonstrated a safety profile consistent with the known characteristics of OCA, with no unexpected safety signals, while supporting sustained efficacy ...
Christopher L. Bowlus, Frederik Nevens, Kris V. Kowdley, Alan Bonder, Thomas Capozza, Jing Li, Radhika Nair, Michael Trauner, David E. Jones   +8 more
wiley   +1 more source

Review article: Immunosuppression in Decompensated Autoimmune Hepatitis Cirrhosis ‐ To Suppress or Not to Suppress?

Alimentary Pharmacology &Therapeutics, EarlyView.
Individualized assessment identifies patients with decompensated autoimmune hepatitis cirrhosis who are likely to benefit from a time‐limited trial of immunosuppression versus those requiring immediate liver transplant evaluation. Early objective response monitoring (bilirubin, MELD‐Na and AST/ALT) guides continuation of immunosuppression, promotes ...
Pedro Robson Costa Passos, Valbert Oliveira Costa Filho, Guilherme Grossi Lopes Cançado   +2 more
wiley   +1 more source